Shares of Clovis Oncology (NASDAQ:CLVS) have earned a consensus recommendation of “Hold” from the fifteen brokerages that are presently covering the stock, MarketBeat.com reports. Two investment analysts have rated the stock with a sell rating, five have issued a hold rating and eight have issued a buy rating on the company. The average twelve-month price objective among analysts that have issued a report on the stock in the last year is $38.00.
Several analysts have recently issued reports on the stock. BidaskClub cut shares of Clovis Oncology from a “hold” rating to a “sell” rating in a research report on Wednesday, March 20th. JPMorgan Chase & Co. reissued a “hold” rating on shares of Clovis Oncology in a research report on Sunday, April 7th. Credit Suisse Group reissued a “buy” rating and set a $29.00 price target on shares of Clovis Oncology in a research report on Wednesday. ValuEngine cut shares of Clovis Oncology from a “hold” rating to a “sell” rating in a research report on Wednesday, May 1st. Finally, Zacks Investment Research raised shares of Clovis Oncology from a “sell” rating to a “hold” rating in a research report on Friday, March 29th.
Shares of CLVS stock opened at $18.74 on Monday. The stock has a market cap of $964.69 million, a price-to-earnings ratio of -2.65 and a beta of 1.89. Clovis Oncology has a 1-year low of $11.50 and a 1-year high of $53.90. The company has a quick ratio of 4.15, a current ratio of 4.39 and a debt-to-equity ratio of 8.04.
Clovis Oncology (NASDAQ:CLVS) last issued its quarterly earnings results on Tuesday, May 7th. The biopharmaceutical company reported ($1.63) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.80) by $0.17. The business had revenue of $33.12 million for the quarter, compared to analysts’ expectations of $32.10 million. Clovis Oncology had a negative net margin of 342.54% and a negative return on equity of 196.39%. The business’s quarterly revenue was up 78.8% on a year-over-year basis. During the same quarter in the prior year, the company earned ($1.38) earnings per share. Equities research analysts anticipate that Clovis Oncology will post -6.75 earnings per share for the current fiscal year.
In related news, Director James C. Blair sold 17,056 shares of the firm’s stock in a transaction that occurred on Thursday, March 14th. The shares were sold at an average price of $27.79, for a total value of $473,986.24. Following the sale, the director now owns 13,439 shares of the company’s stock, valued at $373,469.81. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, insider Lindsey Rolfe sold 1,731 shares of the firm’s stock in a transaction that occurred on Tuesday, March 5th. The shares were sold at an average price of $29.29, for a total transaction of $50,700.99. Following the completion of the sale, the insider now directly owns 16,497 shares in the company, valued at approximately $483,197.13. The disclosure for this sale can be found here. In the last ninety days, insiders sold 20,782 shares of company stock worth $576,755. 8.30% of the stock is owned by corporate insiders.
Large investors have recently modified their holdings of the stock. Pearl River Capital LLC acquired a new stake in Clovis Oncology in the first quarter valued at approximately $40,000. NumerixS Investment Technologies Inc acquired a new stake in Clovis Oncology in the first quarter valued at approximately $62,000. Ladenburg Thalmann Financial Services Inc. raised its holdings in Clovis Oncology by 93.4% in the first quarter. Ladenburg Thalmann Financial Services Inc. now owns 3,146 shares of the biopharmaceutical company’s stock valued at $77,000 after acquiring an additional 1,519 shares in the last quarter. Great West Life Assurance Co. Can raised its holdings in Clovis Oncology by 54.8% in the fourth quarter. Great West Life Assurance Co. Can now owns 7,034 shares of the biopharmaceutical company’s stock valued at $122,000 after acquiring an additional 2,489 shares in the last quarter. Finally, Nelson Van Denburg & Campbell Wealth Management Group LLC acquired a new stake in Clovis Oncology in the first quarter valued at approximately $192,000.
Clovis Oncology Company Profile
Clovis Oncology, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. Its commercial product includes Rubraca (rucaparib) tablet, a small molecule poly ADP-ribose polymerase inhibitor, used as monotherapy for the treatment of patients with deleterious BRCA mutation associated advanced ovarian cancer, who have been treated with two or more chemotherapies, and selected for therapy by an FDA-approved companion diagnostic for Rubraca.
Recommended Story: What is the Federal Reserve?